Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC
Status:
Unknown status
Trial end date:
2020-11-26
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy and safety of Anlotinib plus Pemetrexed as the 1-line treatment of
patients with Platinum intolerant advanced non-squamous NSCLC, with Pemetrexed control.